The Andro/Endo 2025 International Urology and Endocrinology Conference, hosted by the Thai Urological Association (TUA), the Thai Endoscopic Urology Society, and the Thai Men's Health Association, is one of the most influential urology and andrology events in Southeast Asia. This year's conference focuses on the latest clinical advances in sexual health, endocrinology, and minimally invasive urological surgery, with over 200 urologists and andrology specialists from Thailand participating. The agenda includes several keynote speeches, clinical case studies, and live surgical demonstrations.
Key Highlights of the Agenda Include:
1.Latest clinical strategies for the treatment of erectile dysfunction (ED) and premature ejaculation,
2.The application prospects of LIPUS and micro-energy medicine in andrology treatment,
3.Live demonstrations and discussions of endoscopic and minimally invasive surgeries (HoLEP, TFL, Varicocelectomy, etc.),
4.Expert Forum: "How to Become an International Andrology Fellow" (covering training systems in Japan, Canada, the U.S., and more).
Academic Collaboration and Clinical Advancement
The WBL team engaged in in-depth discussions with Dr. Kavirach Tantiwongse, Associate Professor at Chulalongkorn University and one of the chairs of the Thai Urological Association (TUA), to launch the WBL LIPUS clinical donation and research collaboration plan. The application and academic initiation process is expected to be completed within a month.
Dr. Kavirach also invited WBL to participate in the 37th TUA Annual Meeting in 2026, which will be held in April 2026. The official location will be announced later, and the team will continue to monitor the latest updates.
Expert Support and Clinical Recognition
Dr. Apichat, known as the "Father of Thai Urology," visited the WBL booth and highly recognized the clinical potential of WBL LIPUS technology. He also affirmed the contribution of this technology to advancing the male health sector during the banquet.
OHI Team and Market Promotion
The Ouiheng International Healthcare (OHI) team demonstrated excellent professionalism and coordination at the exhibition, assisting physicians with reception, translation, and on-site operations, while actively learning about the clinical applications of WBL LIPUS.
Several Thai urologists and andrology specialists visited the WBL booth to learn more about the WBL LIPUS system and expressed interest in cooperation. OHI will continue to follow up on their needs after the event and strengthen relationships with physicians for clinical collaboration.
Thai FDA Registration and Action Plan
Document Preparation and Review:
OHI's regulatory department, led by Natthamon, has provided the "Full CSDT Checklist for Active Medical Device." The team is currently preparing the full registration documents required by the Thai FDA (including DOC, LOA, IFU, manufacturing processes, clinical data, and risk analysis).
OHI–WBL Collaboration Breakdown:
OHI is responsible for gathering and submitting local regulatory documents；WBL will provide technical documents, product test reports, and ISO13485 quality system certifications.
Estimated Timeline:
The full CSDT documentation is expected to be submitted by the end of December 2025. The preliminary review cycle is expected to take 2-3 months.
Subsequent Plans:
Once the registration is completed, the installation of the first batch of devices will begin, along with clinical training and after-sales support. OHI's regulatory team will continue to follow up on feedback and any additional documentation requests.
WBL LIPUS
This exhibition not only advanced academic collaboration and clinical donations but also strengthened the brand's recognition and trust in the Southeast Asian market. It is expected that registration will be completed by Q2 2026, with clinical cooperation beginning shortly thereafter, further consolidating WBL's academic and clinical presence in the Southeast Asian market.